Mirati Therapeutics Inc. (MRTX)
NASDAQ: MRTX
· Real-Time Price · USD
58.70
-0.10 (-0.17%)
At close: Jan 22, 2024, 10:00 PM
Mirati Therapeutics Balance Sheet Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Cash & Equivalents | 258.72M | 129.87M | 241.93M | 235.26M | 298.84M | 265.6M | 304.7M | 413.08M | 242.62M | 280.72M | 329.5M |
Short-Term Investments | 717.72M | 649.57M | 660.37M | 848.58M | 902.15M | 915.73M | 1.02B | 1.08B | 911.79M | 915.79M | 957.66M |
Long-Term Investments | 3.56M | 4.57M | 3.35M | 3.46M | 1.88M | 2.63M | 3.14M | 8.22M | 11.25M | 8.95M | 11.68M |
Other Long-Term Assets | 620K | 620K | 23.43M | 21.64M | 21.06M | 20.24M | 20.64M | 19.05M | 18.38M | 17.71M | 17.31M |
Receivables | 20.13M | 15.7M | 6.23M | 865K | 1.69M | 1.53M | n/a | 2.51M | 1.96M | n/a | 1.84M |
Inventory | 20.16M | 8.64M | 3.85M | 3.02M | n/a | n/a | n/a | -2.51M | n/a | n/a | n/a |
Other Current Assets | 24.84M | 20.32M | 26.98M | 21.24M | 23.11M | 20.07M | 16.64M | 16.64M | 15.52M | 81.58M | 14.51M |
Total Current Assets | 1.04B | 818.92M | 939.35M | 1.11B | 1.23B | 1.2B | 1.34B | 1.51B | 1.17B | 1.28B | 1.3B |
Property-Plant & Equipment | 51.11M | 52.3M | 52.97M | 53.66M | 54.36M | 53.99M | 54.41M | 53.5M | 51.91M | 50.95M | 48.34M |
Goodwill & Intangibles | 14.14M | 14.4M | 14.65M | 14.91M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Total Long-Term Assets | 93.63M | 96.13M | 94.41M | 93.69M | 77.3M | 76.86M | 78.18M | 80.77M | 81.54M | 77.6M | 77.32M |
Total Assets | 1.13B | 915.04M | 1.03B | 1.2B | 1.3B | 1.28B | 1.42B | 1.59B | 1.25B | 1.36B | 1.38B |
Account Payables | 37.96M | 32.51M | 22.32M | 38.86M | 19.45M | 24.27M | 27.94M | 35.16M | 42.92M | 23.87M | 19.6M |
Deferred Revenue | -8.02M | -7.96M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 65M | n/a |
Short-Term Debt | 8.02M | 7.96M | 7.9M | 7.84M | 7.17M | 4.3M | n/a | n/a | n/a | n/a | n/a |
Other Current Liabilities | 91.4M | 99.52M | 94.38M | 112.74M | 100.37M | 90.58M | 95.63M | 108.5M | 79.16M | 92M | 57.5M |
Total Current Liabilities | 137.38M | 139.99M | 124.6M | 159.45M | 126.99M | 119.15M | 123.57M | 143.66M | 122.08M | 180.87M | 77.11M |
Long-Term Debt | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Long-Term Liabilities | 45.86M | 46.1M | 46.53M | 46.68M | 47.04M | 48.64M | 48.45M | 48.06M | 47.33M | 45.91M | 44.31M |
Total Long-Term Liabilities | 45.86M | 46.1M | 46.53M | 46.68M | 47.04M | 48.64M | 48.45M | 48.06M | 47.33M | 45.91M | 44.31M |
Total Liabilities | 183.24M | 186.09M | 171.13M | 206.13M | 174.03M | 167.79M | 172.02M | 191.72M | 169.41M | 226.78M | 121.42M |
Total Debt | 50.22M | 50.68M | 43.23M | 51.51M | 51.26M | 50.13M | 45.83M | 45.88M | 45.52M | 44.48M | 43.17M |
Common Stock | 70K | 58K | 58K | 58K | 58K | 56K | 56K | 55K | 52K | 52K | 51K |
Retained Earnings | -2.98B | -2.81B | -2.64B | -2.45B | -2.25B | -2.08B | -1.9B | -1.71B | -1.51B | -1.43B | -1.27B |
Comprehensive Income | -1.55M | -1.72M | -1.71M | -3.72M | -6.13M | 3.36M | 4.27M | 9.07M | 9.6M | 9.6M | 9.46M |
Shareholders Equity | 946.47M | 728.95M | 862.63M | 996.52M | 1.13B | 1.11B | 1.25B | 1.4B | 1.08B | 1.13B | 1.26B |
Total Investments | 717.72M | 649.57M | 660.37M | 848.58M | 904.03M | 918.36M | 1.02B | 1.09B | 923.05M | 924.74M | 969.34M |